γ-heregulin is the product of a chromosomal translocation fusing the DOC4 and HGL/NRG1 genes in the MDA-MB-175 breast cancer cell line-Reference-Cited by-同舟云学术

γ-heregulin is the product of a chromosomal translocation fusing the DOC4 and HGL/NRG1 genes in the MDA-MB-175 breast cancer cell line

Published:1999-10 Issue:41 Volume:18 Page:5718-5721
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Wang Xiao-Zhong,Jolicoeur Ethel M,Conte Nathalie,Chaffanet Max,Zhang Yuhong,Mozziconacci Marie-Joëlle,Feiner Helen,Birnbaum Daniel,Pébusque Marie-Josèphe,Ron David

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/1202950.pdf

Reference11 articles.

1. Baumgartner S, Martin D, Hagios C and Chiquet-Ehrismann R. . 1994 EMBO J. 13: 3728–3740.

2. Burden S and Yarden Y. . 1997 Neuron 18: 847–855.

3. Cailleau R, Young R, Olive M and Reeves Jr, WJ. . 1974 J. Natl. Cancer Inst. 53: 661–674.

4. Chaffanet M., Imbert A, Adelaide J, Le Paslier D, Wagner MJ, Wells DE, Birnbaum D and Pebusque MJ. . 1996 Cytogenet Cell Genet 72: 63–68.

5. Imbert A, Chaffanet M, Essioux L, Noguchi T, Adelaide J, Kerangueven F, Le Paslier D, Bonaiti-Pellie C, Sobol H, Birnbaum D and Pebusque MJ. . 1996 Genomics 32: 29–38.

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic and predictive biomarkers in non-small cell lung carcinoma;Pathology;2023-12

2. NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis;Trends in Cancer;2022-03

3. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements;Cancer Discovery;2022-02-08

4. Role and Involvement of TENM4 and miR-708 in Breast Cancer Development and Therapy;Cells;2022-01-05

5. Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers;Journal of Thoracic Oncology;2021-07